Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP
Andrew E. Hendifar, MD
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
June 24, 2026
06:00 PM - 06:45 PM CEST
Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD
Alexander Spira, MD, PhD, FACP
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Roberto Leon-Ferre, MD
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Amy Comander, MD
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Chandrikha Chandrasekharan, MBBS
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.